Skip to main
URGN
URGN logo

UroGen Pharma (URGN) Stock Forecast & Price Target

UroGen Pharma (URGN) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 17%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

UroGen Pharma Ltd has demonstrated significant financial growth, with full-year net product revenue increasing by 9% to $90.4 million in 2024, attributed to the rising demand for its flagship product, JELMYTO, which saw a 15% year-over-year increase in Q4 revenue. The company's projections indicate robust future sales, anticipating $114.1 million in 2025 and escalating to $338.8 million in 2026, bolstered by the promising outcomes of investigational candidate UGN-102, which has shown an 18-month duration of response of 80.6% in clinical trials. Furthermore, UroGen's strategic positioning in a market opportunity exceeding $5 billion, particularly with the potential commercial launch of UGN-102, supports a positive outlook on the company's long-term growth trajectory.

Bears say

UroGen Pharma Ltd reported a full-year 2024 net loss of $2.96 per share, with a notable widening of its Q4 net loss to $37.5 million compared to $26.0 million in the prior-year period, reflecting growing financial challenges. Key risks impacting the company's outlook include heightened competition reducing market penetration, potential clinical failures of investigative candidates, and difficulties in extending market exclusivity for core franchises. Furthermore, the company experienced a modest revenue miss in Q4 2024 with $24.6 million in top-line revenue, prompting adjustments to long-term revenue ramp expectations and necessitating reductions in financial forecasts.

UroGen Pharma (URGN) has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 17% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of UroGen Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About UroGen Pharma (URGN) Forecast

Analysts have given UroGen Pharma (URGN) a Buy based on their latest research and market trends.

According to 12 analysts, UroGen Pharma (URGN) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

UroGen Pharma (URGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.